Crystalline form of tegavivint, method of preparation, and use thereof
US11136307B1 · kind B1 · utility
1Cited by
1References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 29, 2020 |
| Grant date | Oct 5, 2021 |
| Priority date | — |
| Expiry date | Sep 29, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention relates to crystalline forms of (9E,10E)-2,7-bis((3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime, pharmaceutical compositions comprising the crystalline form, processes for preparing the crystalline form and methods of use therefore.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.